Literature DB >> 21112784

Synthesis of a novel human PPARδ selective agonist and its stimulatory effect on oligodendrocyte differentiation.

Shogo Sakuma1, Tsuyoshi Endo, Takashi Kanda, Hideki Nakamura, Satomi Yamasaki, Tomio Yamakawa.   

Abstract

We successfully synthesized a novel peroxisome proliferator-activated receptor (PPAR)δ selective agonist, namely, compound 20, with a characteristic benzisoxazole ring. Compound 20 exhibited potent human PPARδ transactivation activity and high δ selectivity. Further, it stimulated differentiation of primary oligodendrocyte precursor cells in vitro, indicating that it may be an effective drug in the treatment of demyelinating disorders such as multiple sclerosis.
Copyright © 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21112784     DOI: 10.1016/j.bmcl.2010.11.030

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  4 in total

Review 1.  Dissecting the role of peroxisome proliferator-activated receptor-β/δ (PPARβ/δ) in colon, breast, and lung carcinogenesis.

Authors:  Jeffrey M Peters; Jennifer E Foreman; Frank J Gonzalez
Journal:  Cancer Metastasis Rev       Date:  2011-12       Impact factor: 9.264

Review 2.  Nuclear hormone receptors in demyelinating diseases.

Authors:  Rocío I Zorrilla Veloz; Takese McKenzie; Bridgitte E Palacios; Jian Hu
Journal:  J Neuroendocrinol       Date:  2022-06-22       Impact factor: 3.870

3.  3-Benzyl-1-{[3-(4-chloro-phen-yl)isoxazol-5-yl]meth-yl}-1H-benzimidazol-2(3H)-one.

Authors:  Youssef Kandri Rodi; Amal Haoudi; Frédéric Capet; Christian Rolando; Lahcen El Ammari
Journal:  Acta Crystallogr Sect E Struct Rep Online       Date:  2013-08-17

Review 4.  Metabolic Dysfunction and Peroxisome Proliferator-Activated Receptors (PPAR) in Multiple Sclerosis.

Authors:  Véronique Ferret-Sena; Carlos Capela; Armando Sena
Journal:  Int J Mol Sci       Date:  2018-06-01       Impact factor: 5.923

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.